Who is sponsoring NCT00823901?

NCT00823901 is sponsored by Massachusetts General Hospital.

What drugs are being tested in NCT00823901?

Interventions: Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel, Placebo gel.

What is the status of NCT00823901?

NCT00823901 is currently COMPLETED.

Last reviewed 2012-06-19 · How we verify

A Double-Blind, Placebo-Controlled, Pilot Study to Determine the Safety and Efficacy of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel For The Treatment of Rosacea Over 12 Weeks

NCT00823901 Phase 2/Phase 3 COMPLETED Results posted

The purpose of this study is to determine whether Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel are effective and safe in the treatment of papulopustular rosacea.

Details

Lead sponsor	Massachusetts General Hospital
Phase	Phase 2/Phase 3
Status	COMPLETED
Enrolment	83
Start date	2009-02
Completion	2010-10

Conditions

Rosacea

Interventions

Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel
Placebo gel

Primary outcomes

Mean Change in Number of Inflammatory Lesions From Baseline to Week 12 — Baseline, week 12
The number of inflammatory lesions (papules and pustules) on the face were counted by a dermatologist at baseline and week 12 for each participant. Change in the number of inflammatory lesions is defined as week 12 values minus the baseline values of the participant. Last observation carried forward (LOCF) method was used for missing values.

Countries

United States